Gilead Sciences | GenomeWeb

Gilead Sciences

The lead investigators said that Foundation Medicine's NGS test will enable the beginning of targeted treatment within seven days of diagnosis. 

Lasker Honorees

The Albert and Mary Lasker Foundation has announced this year's recipients of its prizes honoring basic and clinical research.

NEW YORK (GenomeWeb) – The Yale School of Medicine today said that it and Gilead Sciences have extended a research collaboration to identify the genetic and molecular bases of cancer.

NEW YORK (GenomeWeb News) – Cancer Genetics today announced that Gilead Sciences has selected it to provide clinical trial services and molecular profiling of chronic lymphocytic leukemia patients.

NEW YORK (GenomeWeb News) – SomaLogic, New England Biolabs, and Gilead Sciences are suing Enzymatics in federal court for patent infringement.

This story originally ran on Dec. 22.
By Adam Bonislawski

Gilead is funding up to $100 million to the collaboration, which is aimed at identifying new molecular targets for the development of new cancer treatments.

Movers & Shakers

Premium

Leroy Hood, Samuel Broder, Mark Velleca, Paul Beresford, Dino DiCamillo

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.